Novel Primate T-cell Lymphotropic Viruses (HTLV, STLV) for Development of Diagnostics, Therapeutics, Research Tools, and Vaccines
Rapid Detection of Antiretroviral(s) Drug-Resistant HIV-1 within Clinical Samples
Select M. tuberculosis Peptides as Mucosal Vaccines Against Pulmonary Tuberculosis
Molecular Detection and Viral-Load Quantification for HIV-1 Groups M, N and O, and Simian Immunodeficiency Virus-cpz (SIVcpz)
Simple, Rapid, and Sensitive Real-Time PCR Assays for Detecting Drug Resistance of HIV
Multiplexing Homocysteine in Primary Newborn Screening Assays Using Maleimides as Select Derivatization Agents
An Automated System for Myocardial Perfusion Mapping and Machine Diagnosis to Detect Ischemic Heart Disease with First-pass Perfusion Cardiac Magnetic Resonance Imaging
This technology includes a fully automated computer aided diagnosis system to quantify myocardial blood flow (MBF) and myocardial perfusion reserve (MPR) pixel maps from the first-pass contrast-enhanced cardiac magnetic resonance (CMR) perfusion images. This system performs automated image registration, motion compensation, segmentation, and modeling to extract quantitative features from different myocardial regions of interest.
Next-Generation 5-HT-2B Serotonin-Receptor Antagonists for Anti-Fibrotic & Cardiopulmonary Therapy
This technology includes a family of small-molecule antagonists that selectively block the 5-HT2B serotonin receptor—an upstream driver of tissue-remodeling—to address fibrotic, cardiopulmonary and related disorders. Built on a conformationally-locked “(N)-methanocarba” nucleoside scaffold, the compounds show nanomolar potency, >30–400-fold selectivity over the closely related 5-HT2C receptor, and favorable oral bioavailability in rodents.
Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness
Targeted toxins (e.g., immunotoxins) are therapeutics that have at least two important components: (1) a toxin domain that is capable of killing cells and (2) a targeting domain that is capable of selectively localizing the toxic domain to only those cells which should be killed. By selecting a targeting domain that binds only to certain diseased cells (e.g., a cell which only expresses a cell surface receptor when in a diseased state), targeted toxins can kill the diseased cells while allowing healthy, essential cells to survive.